Device provides relief from meibomian gland dysfunction; enables view

Systane iLux2, from Alcon, is an upgraded model of the original Systane iLux2 system, designed to capture infrared photos of the meibomian glands and treat meibomian gland dysfunction (MGD) with thermal pulsation. The upgraded model is a welcomed addition to my arsenal against dry eye disease for the following reasons:

IMAGE CAPTURE

The device lets both the eye care provider and their patient see their gland blockage via an infrared video of the pulsation procedure and, thus, aid in confirming the diagnosis of MGD, while also showing the device’s effectiveness post-pulsation, which can be up to 12 months.

THERMAL PULSATION

With Systane iLux2, it’s possible to address MGD, a root cause of dry eye disease (DED).

Specifically, the device gently unblocks the meibomian glands, while improving gland secretions scores, restores a healthy tear film and, thus, reduces the symptoms of MGD, such as dry and gritty eyes.

Something else to consider: My patients who have undergone Systane iLux2 have also reported experiencing significantly reduced light sensitivity, blurry, and poor vision.

PATIENT RELATIONSHIP BUILDING

I have found that the device has helped me to build a strong, trusting relationship with patients, as it has shown them I’m up to date on the latest advances in DED management, and it boosts my credibility as their eye care provider through its direct visualization of MGD and my ability to track the chronic condition over time through stored meibomian gland images.

Patients have been particularly impressed with the fact that the Systane iLux2 stabilizes their tear film prior to surgery. Over half of cataract patients have signs of MGD¹ and could, therefore, benefit from treatment with this device.

Further, educating the patient how the procedure benefits them now, while also preparing them for why additional treatments may be necessary are other ways the device aids in the doctor-patient relationship.

UNFORGETTABLE CASES

I see several patients who present to my practice complaining of DED symptoms, such as those mentioned above. It is so gratifying to be able to bring relief to these patients with the DED treatments I prescribe. In the case of employing Systane iLux2, one patient case comes to mind.

Specifically, the patient was using a prescription, anti-inflammatory eyedrop to treat her MGD, though she said she was still experiencing fluctuating vision. Examination revealed 50% gland dropout, which I showed her prior to recommending she undergo the Systane iLux2 Thermal Pulsation System.

After the procedure, I was able to show her a video of the successful expression of her meibomian glands. The patient reported improved vision and long-lasting symptom relief.

For additional information on the device, check out https://ilux.myalcon.com . OM

REFERENCE

1. Cochener B, Cassan A, Omiel L. Prevalence of meibomian gland dysfunction at the time of cataract surgery. J Cataract Refract Surg. 2018 Feb;44(2):144-148. doi: 10.1016/j.jcrs.2017.10.050.

DR. WHITLEY is director of optometric services at Virginia Eye Consultants, an optometry/ophthalmology tertiary referral center with five locations throughout the state. He is also residency program supervisor for the Salus University Pennsylvania College of Optometry. Dr. Whitley is a paid consultant for Alcon Systane iLux2.